NCT01257815已完成4 期
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment. A UK, 18-month, Prospective, Open-label, Multicentre, Single-arm, Phase IIIb Study With 12-month Primary Endpoint, Assessing the Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Diabetic Macular Oedema.
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 111
- 试验地点
- 1
- 主要终点
- The change in mean Best Corrected Visual Acuity (BCVA)
研究概览
简要总结
This study evaluates a new investigational treatment regimen of three consecutive monthly doses of ranibizumab followed by an as-needed treatment regimen, with monthly follow-up for the first three months then two-monthly follow-up until 18 months in patients with visual impairment due to diabetic macular oedema.The aim of the study is to determine if this treatment regimen is effective and safe in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Type 1 or Type 2 diabetes mellitus.
- •Patients with visual impairment due to focal or diffuse diabetic macular oedema (DMO), and not other causes, in at least one eye who are eligible for laser treatment in the opinion of the investigator.
- •Best Corrected Visual Acuity between 78 and 24 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS)-like grading charts (approximate Snellen equivalent of 20/32 to 20/320).
- •Increased central retinal thickness which, in the opinion of the investigator, is due to DMO.
排除标准
- •Concomitant conditions in the study eye that could prevent the improvement of visual acuity on study treatment.
- •Active intraocular inflammation (grade trace or above) or infection in either eye at enrollment.
- •History of uveitis in either eye at any time.
- •Structural damage within 0.5 disc diameters of the centre of the macular in the study eye likely to preclude improvement in visual acuity following resolution of macular oedema.
- •Planned medical or surgical intervention during the 18-month study period.
- •Uncontrolled glaucoma in either eye at screening.
- •Blood pressure systolic > 160 mmHg or diastolic > 100 mmHg at screening.
- •Ocular conditions in the study eye that require chronic concomitant therapy with topical ocular or systemically administered corticosteroids.
- •History of acute thromboembolic event within 4 months of screening.
- •Untreated diabetes mellitus.
- •Evidence of advanced, severe or unstable concomitant disease or its treatment which may interfere with evaluations or put the patient at special risk.
- •Other protocol-defined inclusion/exclusion criteria may apply
研究组 & 干预措施
Ranibizumab 0.5mg
Experimental
干预措施: Ranibizumab (Drug)
结局指标
主要结局
The change in mean Best Corrected Visual Acuity (BCVA)
时间窗: Baseline to 12 months
次要结局
- The change in mean Best Corrected Visual Acuity (BCVA)(Baseline to 18 months)
- Time course of changes in central retinal thickness(From baseline and 6 months to 12 and 18 months)
- Proportion of patients with 10 and 15 letter improvement or loss in BCVA(From baseline to 12 and 18 months)
- Occurrence of ocular and systemic adverse events(Baseline to 18 months)
- Time course of changes in BCVA(From 6 to 12 and 18 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment EvaluationDiabetic RetinopathyNCT01223612Moorfields Eye Hospital NHS Foundation Trust37
Unknown
1 期
Ranibizumab For Persistent Diabetic Macular Edema After BevacizumabDiabetic Macular EdemaNCT01845844Southeast Retina Center, Georgia30
已完成
2 期
Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF TherapyDiabetic Macular EdemaNCT01472510Vitreo-Retinal Associates, PC20
已完成
2 期
Dosing Study of Ranibizumab for Diabetic Retinal and Macular EdemaMacular EdemaDiabetic RetinopathyNCT01476449Retina Vitreous Associates of Florida20
已完成
不适用
Evaluation of Ranibizumab for diabetes macular edemadiabetes macular edemaJPRN-UMIN000001984Yamagata University faculty of Medecine,department of ophthalmology10